Medicenna Therapeutics Corp.
Index- P/E- EPS (ttm)-0.47 Insider Own33.20% Shs Outstand54.00M Perf Week5.94%
Market Cap66.49M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float37.27M Perf Month-10.92%
Income-25.20M PEG- EPS next Q-0.10 Inst Own7.39% Short Float0.70% Perf Quarter-38.73%
Sales- P/S- EPS this Y-34.20% Inst Trans- Short Ratio2.29 Perf Half Y-55.46%
Book/sh0.44 P/B2.41 EPS next Y- ROA-74.20% Target Price- Perf Year-68.36%
Cash/sh0.37 P/C2.84 EPS next 5Y- ROE-84.70% 52W Range0.91 - 4.02 Perf YTD-34.97%
Dividend- P/FCF- EPS past 5Y-32.60% ROI- 52W High-73.63% Beta0.49
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low16.23% ATR0.11
Employees13 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)43.99 Volatility10.25% 9.12%
OptionableNo Debt/Eq0.00 EPS Q/Q17.90% Profit Margin- Rel Volume0.14 Prev Close1.10
ShortableYes LT Debt/Eq0.00 EarningsFeb 09 BMO Payout- Avg Volume114.46K Price1.06
Recom- SMA20-3.10% SMA50-12.55% SMA200-42.00% Volume15,583 Change-3.64%
Dec-18-20Initiated Oppenheimer Outperform $12
May-11-22 07:00AM  
May-10-22 03:13PM  
May-02-22 08:00AM  
Apr-27-22 07:00AM  
Apr-08-22 09:15AM  
Mar-15-22 08:28AM  
Mar-10-22 07:00AM  
Mar-09-22 07:00AM  
Mar-03-22 07:00AM  
Feb-15-22 05:57AM  
Feb-10-22 07:00AM  
Feb-09-22 07:00AM  
Feb-02-22 07:30AM  
Jan-31-22 07:00AM  
Jan-26-22 07:00AM  
Jan-17-22 06:00PM  
Jan-05-22 07:00AM  
Dec-22-21 08:14AM  
Dec-17-21 07:00AM  
Dec-16-21 06:38PM  
Dec-14-21 12:38AM  
Nov-18-21 07:00AM  
Nov-16-21 05:20AM  
Nov-12-21 09:00AM  
Nov-09-21 07:00AM  
Nov-04-21 08:00AM  
Oct-27-21 08:00AM  
Oct-07-21 09:05AM  
Sep-23-21 04:30PM  
Sep-22-21 08:00AM  
Sep-20-21 08:00AM  
Sep-14-21 08:00AM  
Sep-09-21 09:00AM  
Aug-18-21 08:19AM  
Aug-13-21 07:00AM  
Aug-04-21 09:00AM  
Jul-27-21 09:00AM  
Jul-20-21 09:40AM  
Jul-14-21 09:00AM  
Jun-28-21 06:22AM  
Jun-23-21 09:00AM  
Jun-21-21 05:30PM  
Jun-02-21 06:10AM  
May-28-21 07:30AM  
May-21-21 05:33AM  
May-20-21 09:00AM  
May-12-21 09:00AM  
May-07-21 12:02PM  
Apr-21-21 09:10AM  
Apr-14-21 09:00AM  
Apr-12-21 07:00AM  
Apr-08-21 12:46PM  
Mar-25-21 07:00AM  
Mar-11-21 07:00AM  
Mar-04-21 07:00AM  
Feb-22-21 07:00AM  
Feb-17-21 07:00AM  
Feb-12-21 07:00AM  
Dec-30-20 06:10PM  
Dec-23-20 03:41AM  
Dec-09-20 07:00AM  
Dec-04-20 03:03AM  
Dec-02-20 07:00AM  
Nov-23-20 07:30AM  
Nov-19-20 12:39PM  
Nov-18-20 07:00AM  
Nov-13-20 07:00AM  
Nov-02-20 07:30AM  
Oct-26-20 08:00AM  
Oct-20-20 06:27AM  
Oct-19-20 07:00AM  
Oct-15-20 05:30PM  
Sep-30-20 04:30PM  
Sep-09-20 07:00AM  
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.